Hydrocortison-Pos N (Hydrocortisone Acetate)

Hydrocortison-Pos N is used in ophthalmic care to address inflammatory conditions of the eye.

• Management of mild to moderate allergic conjunctivitis.
• Reduction of postoperative inflammation following cataract or refractive surgery.
• Treatment of anterior uveitis or iritis to control intra‑ocular inflammation.
• Relief of inflammatory ocular surface disorders such as keratitis or dry eye‑related inflammation.
• Control of corneal edema associated with inflammatory processes.
• Adjunct therapy for ocular allergic reactions that do not respond adequately to antihistamine drops.
• Short‑term use to manage inflammatory flare‑ups in contact lens‑related keratitis.

• Hydrocortison-Pos N delivers hydrocortisone acetate to ocular tissues, where it diffuses across cell membranes and binds to intracellular glucocorticoid receptors. The receptor‑ligand complex translocates to the nucleus and interacts with glucocorticoid response elements, modulating gene transcription. This results in decreased synthesis of pro‑inflammatory cytokines, prostaglandins, and leukotrienes, while enhancing the expression of anti‑inflammatory proteins, thereby reducing ocular inflammation and overall edema.

Like other ocular corticosteroids, Hydrocortison-Pos N may be associated with local and systemic adverse reactions, although many patients tolerate it without significant problems.

Common

• Transient stinging or burning sensation upon instillation.
• Mild conjunctival hyperemia.
• Temporary increase in intra‑ocular pressure that resolves after discontinuation.
• Blurred vision that improves with continued use.
• Localized eyelid irritation or pruritus.
• Increased tear production or watery eyes.

Serious

• Persistent elevation of intra‑ocular pressure leading to glaucoma.
• Development of cataract formation with prolonged use.
• Secondary ocular infection such as bacterial or fungal keratitis.
• Delayed wound healing after ocular surgery.
• Severe allergic reaction manifesting as angioedema or anaphylaxis (rare).
• Corneal thinning or ulceration with chronic therapy.

When prescribing or using Hydrocortison-Pos N, clinicians and patients should observe several precautionary measures to minimize risks and ensure safe therapy.

• Measure intra‑ocular pressure before starting and monitor periodically.
• Use the minimum effective dose for the shortest necessary time.
• Avoid in eyes with active bacterial, viral, or fungal infection.
• Exercise caution in patients with glaucoma or a history of steroid‑induced pressure rise.
• Do not wear contact lenses during treatment unless directed by an eye‑care professional.
• Discuss potential risks with pregnant or nursing women, as data are limited.
• Stop treatment and seek care if significant pressure increase or infection develops.

Hydrocortison-Pos N may interact with other ophthalmic or systemic agents, influencing its efficacy or safety profile.

Avoid

• Concurrent use with other topical corticosteroids, which can markedly increase intra‑ocular pressure.
• Simultaneous administration of non‑steroidal anti‑inflammatory eye drops, which may reduce anti‑inflammatory effectiveness.
• Use with potent ocular vasoconstrictors that could exacerbate ocular hypertension.
• Co‑administration with ocular prostaglandin analogs for glaucoma, which may counteract steroid‑induced pressure elevation.

Use with caution

• Systemic corticosteroids, as additive systemic exposure may raise the risk of systemic side effects.
• Antifungal eye preparations, because combined immunosuppression may predispose to infection.
• Beta‑blocker eye drops, which can mask signs of rising intra‑ocular pressure.